Story perspectives

New Insights on RNA Mutations: Hope for AML Treatment

9/20/2025

28 4

Summary

Story summary

The P95H mutation in SRSF2 disrupts RNA splicing, leading to poor prognosis in acute myeloid leukemia (AML).
TET2 mutations are prevalent in AML, affecting hematopoiesis and correlating with lower survival rates.
NSUN2 stabilizes mRNAs essential for metabolism and AML progression through methylation.
m5C marks influence RNA metabolism and chromatin structure, impacting disease advancement.
Targeting m5C methyltransferases could enhance treatment responses to hypomethylating agents.

1 of 1

Story summary

The P95H mutation in SRSF2 disrupts RNA splicing, leading to poor prognosis in acute myeloid leukemia (AML).
TET2 mutations are prevalent in AML, affecting hematopoiesis and correlating with lower survival rates.
NSUN2 stabilizes mRNAs essential for metabolism and AML progression through methylation.
m5C marks influence RNA metabolism and chromatin structure, impacting disease advancement.
Targeting m5C methyltransferases could enhance treatment responses to hypomethylating agents.